Important Investor Alert: Pacira BioSciences, Inc. Securities Class Action Lawsuit
New Orleans, LA, February 25, 2025. Kahn Swick & Foti, LLC (“KSF”) and its partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until March 14, 2025 to file lead plaintiff applications in a securities class action lawsuit against Pacira BioSciences, Inc. (the “Company”) if they purchased the Company’s securities between August 2, 2023 and August 8, 2024, inclusive (the “Class Period”). This action is pending in the United States District Court for the District of New Jersey.
Background
Pacira BioSciences, Inc. is a biopharmaceutical company engaged in the research, development, manufacturing, and commercialization of non-opioid and opioid pain management and regenerative health solutions. During the Class Period, the Company issued positive statements regarding its financial performance and future prospects.
Alleged False Statements
The complaint alleges that the Company made materially false and misleading statements regarding its business, operational, and financial metrics. Specifically, the Company is accused of understating the risks associated with its flagship product, EXPAREL, and overstating its financial performance.
Impact on Individual Investors
If the allegations in the complaint are proven, individual investors who purchased Pacira BioSciences securities during the Class Period may be entitled to compensation. The lead plaintiff will act on behalf of all other class members in the lawsuit. The lead plaintiff will be appointed by the court and will have the primary responsibility of directing the litigation.
Impact on the World
The securities class action lawsuit against Pacira BioSciences could have far-reaching consequences. It may result in increased scrutiny of the Company’s business practices and financial reporting. Additionally, it could impact investor confidence in the biopharmaceutical industry as a whole. If the allegations are proven, it may lead to increased regulation and oversight of the industry.
Conclusion
Investors who purchased Pacira BioSciences securities during the Class Period should be aware of the ongoing securities class action lawsuit and their potential eligibility for compensation. If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests, please contact KSF at [email protected] or 1-877-515-1850. The deadline to apply for lead plaintiff status is March 14, 2025.
- Investors who purchased Pacira BioSciences securities during the Class Period may be entitled to compensation.
- The lead plaintiff will act on behalf of all other class members in the lawsuit.
- The lawsuit could result in increased scrutiny of the Company’s business practices and financial reporting.
- It could impact investor confidence in the biopharmaceutical industry as a whole.
- The deadline to apply for lead plaintiff status is March 14, 2025.
